secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunocore Holdings plc (IMCR)
CIK:        0001671927
Form:       8-K
Filed at:   2026-09-14T11:15:04+00:00
Accession:  0001671927-26-000026
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunocore achieves 540-patient target enrollment in Phase 3 TEBE-AM trial of tebentafusp in post-PD1 melanoma
--------------------------------------------------------------------------------

- TEBE-AM enrolled 540 patients; randomized Phase 3 trial of tebentafusp ± pembrolizumab vs investigator's choice in HLA-A*02:01+ advanced melanoma.
- Primary endpoint overall survival; topline data expected as early as end of 2026.
- Trial targets previously treated post-PD1 advanced melanoma; potential addressable population ~4,000 patients in US/EU.
- Registrational trial; enrollment milestone supports KIMMTRAK expansion beyond first-line uveal melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/0001671927-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/imcr-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001671927-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer